



# INTERNATIONAL COMMISSION ON THE CLINICAL USE OF HUMAN GERMLINE GENOME EDITING

**Second Meeting**  
**14 November: The National Gallery**  
**15 November: The Royal Society**  
**London, United Kingdom**

## **Preliminary Agenda**

### Meeting Objective:

- *To obtain information to assist in addressing the Commission's Statement of Task*

### 14 November

- 9:00 AM      **Welcome and Introductions** - Commission Co-chairs
- 9:15 AM      **Session 1: International Perspective and Responses to Call for Evidence**  
*(Organized in collaboration with the InterAcademy Partnership)*  
Speakers will provide perspectives on human germline genome editing, discuss issues raised by the Commission's call for evidence and the work of the Commission.
- 10:45 AM      Break
- 11:00 AM      **Session 2: Alternative Reproductive Technologies**  
Speakers will discuss alternatives to germline genome editing, including IVF with PGD, in terms of how applicable they are to certain inheritable diseases, their success rates, if and how they could be improved, how accessible they are internationally, how accepted they are by different cultures, cost/benefit analysis, and other issues
- 12:30          Lunch
- 13:30          **Session 3: The Future of Germline Genome Editing**  
Speakers will discuss how human germline genome editing might work in practice, how the accuracy of germline editing could be improved including through technologies such as base editing, and what we can learn from animal models
- 15:15          Break
- 15:30          **Session 4: Governance**  
*(Organized in collaboration with the World Health Organisation)*  
Speakers will discuss issues associated with scientific integrity and oversight, such as how someone could raise concerns about what is being undertaken in clinical research/application, and how to prevent risk havens for germline editing.
- 17:15 PM      **End of First Day**

15 November

8:30 AM      **Reflections on Day 1 and Introduction to Day 2** - Commission Co-chairs

8:45 AM      **Session 5: Risk-Benefit Analysis in Relation to Rights of Future People and Long Term Follow Up**

Speakers will discuss how the rights of future people have been considered and established in other medical and non-medical scenarios, and how consenting to any necessary or preferred long term follow up on behalf of future generations could be established. The session will also consider potential population effects of enabling human germline genome editing

10:15 AM      Break

10:30 AM      **Session 6: Components of a Potential Translational Pathway**

Speakers will discuss potential use cases for human germline genome editing and the components that would form part of a potential translational pathway, should society conclude that heritable editing applications are acceptable. The session will incorporate a variety of perspectives

11:45 AM      **Closing Remarks for the Workshop**

12:00 PM      **Adjourn**